Hyperbilirubinemia, NeonatalNCT01762189
The Incidence and Risk Factors of Neonatal Hyperbilirubinemia in Term and Late-preterm Chinese Infants
An observational study of Hyperbilirubinemia, Neonatal, run by Nanjing Medical University at 14 sites in China.
Trial summary
Thirteen hospitals in China will participate in the study, which aims to provide data on serum bilirubin levels in the first 168 hr after birth in term and late-preterm neonates, and estimate the incidence of severe neonatal hyperbilirubinemia and the underlying causes. Read more about this study
- Who is it for?
- Ages 1 day to 28 daysHealthy volunteers can take part
- Conditions the study is for
- Hyperbilirubinemia, Neonatal
- What is being tested?
- Phototherapy
- Type of treatment
- Surgery or procedure
- How many people
- 13,157 participants
- Where
- 14 sitesChina
- Study dates
- Jan 2013to Dec 2013
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 day to 28 days
- All sexes
- Healthy volunteers accepted
- Child
Study population: Term or late-preterm newborn infants from Seventeen hospitals in China were recruited.
Who may be able to join
- Term or late-preterm newborn infants with GAs of ≥35 weeks and birth weights of ≥2,000 g were included.
Who cannot join
- All sick newborn infants who were admitted to the intensive care unit.
Trial locations and contacts
14 sites in 1 country.
14 sites in 1 country
China14 sites
The Third Hospital of Peking University
Beijing, 100191
Jinlin Provincial Maternal and Child Health Hospital
Changchun, Jilin, 130021
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072
Guangdong Maternal and Children's Hospital, Guangzhou Medical College
Guangzhou, Guangdong, 510010
Guiyang Maternal and Child Health Hospital
Guiyang, Guizhou, 550003
The First Hospital of Harbin Medical University
Harbin, Heilongjiang, 150001
Inner Mongolia Maternal and Child Health Care Hospital
Hohhot, Inner Mongolia, 010020
Guangxi Maternal and Child Health Hospital
Liuzhou, Guangxi, 530003
Nanjing Maternity and Child Health Care Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210004
Gynecology and Obstetrics Hospital, Fudan University
Shanghai, 200011
Children's Hospital of Fudan University
Shanghai, 200032
Shaanxi Provincial Maternal and Child Health Hospital
Taiyuan, Shaanxi, 300013
The First Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 830054
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 410100
About this study
Official title: Multicenter Prospective Study on the Incidence and Risk Factors of Neonatal Hyperbilirubinemia in Term and Late-preterm Chinese Infants
Thirteen hospitals in China will participate in the study, which aims to provide data on serum bilirubin levels in the first 168 hr after birth in term and late-preterm neonates, and estimate the incidence of severe neonatal hyperbilirubinemia and the underlying causes.
We hypothesize that the study can be value in identifying and implementing strategies for risk reduction.
Read the detailed description
Neonatal hyperbilirubinemia resulting in clinical jaundice is a common problem among infants, particularly during the first weeks of life.
Information about the incidence and risk factors of neonatal jaundice is not available from China where is one of the highest countries of the incidence of severe neonatal hyperbilirubinemia.
- Conditions
- Hyperbilirubinemia, Neonatal
- Being tested
- Phototherapy
- Keywords
- Hyperbilirubinemia, Neonatal, Incidence, Risk factors
- Medical subject headings
- Hyperbilirubinemia, Neonatal, Hyperbilirubinemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PhototherapyProcedure or surgery
The decision to use phototherapy conformed to the hour-specific threshold value for phototherapy presented by the American Academy of Pediatrics guidelines and was not at the discretion of the investigators.
What is being measured
The primary outcome is the main question the study is designed to answer.
The incidence of severe neonatal hyperbilirubinemia
Significant hyperbilirubinemia was defined as any TSB level that exceeded the hour-specific threshold value for phototherapy, according to the guidelines presented by the American Academy of Pediatrics.
Measured: At the 28 days after birth
Secondary outcomes (1)
Number of participants with risk factors associated with severe neonatal hyperbilirubinemia
The risk factors recognized to be associated with significant hyperbilirubinemia in newborns have included gestational age, weight for Gestational Age, delivery mode, gender, previous infant had phototherapy, bruising/cephalahematoma, feeding mode, excessive body weight loss, and early discharge, et al.
Measured: At the 28 days after birth
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2013 (estimated)
- Study startJan 2013
- Primary completionDec 2013
- Study completionDec 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hyperbilirubinemia, NeonatalStudies of the same condition, open and under way.
- More trials run by Nanjing Medical UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 13,157 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nanjing Medical University
- Sponsor type
- University, hospital or other
- Collaborators
- Children's Hospital of Fudan University, Nanjing Maternity and Child Health Care Hospital, Jinlin Provincial Maternal and Child Health Hospital, Peking University Third Hospital, Inner Mongolia Maternal and Child Health Care Hospital, Shanxi Provincial Maternity and Children's Hospital, Obstetrics & Gynecology Hospital of Fudan University, Guangdong Women and Children Hospital, Guangxi Maternal and Child Health Hospital, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, First Affiliated Hospital of Harbin Medical University, Sichuan Provincial People's Hospital, Guiyang Maternity and Child Health Care Hospital
- Responsible party
- Principal investigator, Zhangbin Yu, Nanjing Medical University
- Investigators
- Chao Chen, PhD, Study director, Children's Hospital of Fudan UniversityShuping Han, PhD, Study director, Nanjing Maternity and Child Health Care HospitalZhangbin Yu, PhD, Principal investigator, Nanjing Maternity and Child Health Care HospitalChunming Jiang, PhD, Principal investigator, First Affiliated Hospital of Harbin Medical UniversityYan Gao, PhD, Principal investigator, Jinlin Provincial Maternal and Child Health HospitalXiaomei Tong, PhD, Principal investigator, Peking University Third HospitalMeihua Pu, PhD, Principal investigator, Peking University Third HospitalHongyun Wang, PhD, Principal investigator, Inner Mongolia Maternal and Child Health Care Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01762189
- Sponsor's protocol ID
- NMU-FY2012-319
- Status last verified
- Oct 2014
- First submitted
- 2 Jan 2013
- Last updated
- 28 Oct 2014
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multicenter Prospective Study on the Incidence and Risk Factors of Neonatal Hyperbilirubinemia in Term and Late-preterm Chinese Infants
- ClinicalTrials.gov ID
- NCT01762189
- Acronym / sponsor ID
- NMU-FY2012-319
- Conditions
- Hyperbilirubinemia, Neonatal
- Keywords
- Hyperbilirubinemia, Neonatal, Incidence, Risk factors
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 13,157 participants (actual)
- Lead sponsor
- Nanjing Medical UniversityUniversity, hospital or other
- Collaborators
- Children's Hospital of Fudan University, Nanjing Maternity and Child Health Care Hospital, Jinlin Provincial Maternal and Child Health Hospital, Peking University Third Hospital, Inner Mongolia Maternal and Child Health Care Hospital, Shanxi Provincial Maternity and Children's Hospital, Obstetrics & Gynecology Hospital of Fudan University, Guangdong Women and Children Hospital, Guangxi Maternal and Child Health Hospital, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, First Affiliated Hospital of Harbin Medical University, Sichuan Provincial People's Hospital, Guiyang Maternity and Child Health Care Hospital
- Study start
- Jan 2013
- Primary completion
- Dec 2013 (actual)
- Study completion
- Dec 2013 (actual)
- First posted
- 7 Jan 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Thirteen hospitals in China will participate in the study, which aims to provide data on serum bilirubin levels in the first 168 hr after birth in term and late-preterm neonates, and estimate the incidence of severe neonatal hyperbilirubinemia and the underlying causes.
We hypothesize that the study can be value in identifying and implementing strategies for risk reduction.
Detailed description
Neonatal hyperbilirubinemia resulting in clinical jaundice is a common problem among infants, particularly during the first weeks of life.
Information about the incidence and risk factors of neonatal jaundice is not available from China where is one of the highest countries of the incidence of severe neonatal hyperbilirubinemia.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 1 day to 28 days
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- Term or late-preterm newborn infants from Seventeen hospitals in China were recruited.
Key inclusion criteria (1 listed)
- Term or late-preterm newborn infants with GAs of ≥35 weeks and birth weights of ≥2,000 g were included.
Key exclusion criteria (1 listed)
- All sick newborn infants who were admitted to the intensive care unit.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PhototherapyThe decision to use phototherapy conformed to the hour-specific threshold value for phototherapy presented by the American Academy of Pediatrics guidelines and was not at the discretion of the investigators. | Procedure or surgery | – |
Primary outcome
The incidence of severe neonatal hyperbilirubinemia
Time frame: At the 28 days after birth
Significant hyperbilirubinemia was defined as any TSB level that exceeded the hour-specific threshold value for phototherapy, according to the guidelines presented by the American Academy of Pediatrics.
1 secondary outcome
Number of participants with risk factors associated with severe neonatal hyperbilirubinemia
Time frame: At the 28 days after birth
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2014.
Related trials for Hyperbilirubinemia, Neonatal
Recruiting
Abdominal Massage for Newborn Jaundice
Neonatal Jaundice
Recruiting
Foot Reflexology and Massage in Neonates Receiving Phototherapy
Neonatal Hyperbilirubinemia
Active, not recruiting
Paternal Involvement in Nursing Guidance and Breastfeeding Self-Efficacy in Mothers of High-Risk Newborns
Prematurity, Low Birth Weight
Active, not recruiting
Newborn Abdominal Massage to Prevent Hyperbilirubinemia
Newborn Jaundice
Not yet recruiting
Efficacy of Bifidobacterium Animalis Subsp. Lactis in the Treatment of Indirect Hyperbilirubinemia in Term Neonates
Indirect Hyperbilirubinemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chao Chen, PhD study director
Children's Hospital of Fudan University
Shuping Han, PhD study director
Nanjing Maternity and Child Health Care Hospital
Zhangbin Yu, PhD principal investigator
Nanjing Maternity and Child Health Care Hospital
14 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hyperbilirubinemia, Neonatal, run by Nanjing Medical University at 14 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 14 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The incidence of severe neonatal hyperbilirubinemia (time frame: At the 28 days after birth). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2014.